Johnston S - Search Results

1

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.

Goetz MP, Hamilton EP, Campone M, Hurvitz SA, Cortes J, Johnston S, Llombart-Cussac A, Kaufman PA, Toi M, Jerusalem G, Graham H, Wang H, Jansen VM, Litchfield LM, Martin M. Goetz MP, et al. Among authors: johnston s. Clin Cancer Res. 2024 May 15;30(10):2233-2244. doi: 10.1158/1078-0432.CCR-22-3573. Clin Cancer Res. 2024. PMID: 37889120 Free PMC article. Clinical Trial.

2

Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.

Johnston SR, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M. Johnston SR, et al. Cancer Res. 1994 Nov 15;54(22):5875-81. Cancer Res. 1994. PMID: 7954417 Clinical Trial.

3

Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.

Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC. Johnston SR, et al. Cancer Res. 1997 Sep 1;57(17):3723-7. Cancer Res. 1997. PMID: 9288779

4

Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

Newby JC, Johnston SR, Smith IE, Dowsett M. Newby JC, et al. Among authors: johnston sr. Clin Cancer Res. 1997 Sep;3(9):1643-51. Clin Cancer Res. 1997. PMID: 9815855

5

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. Dowsett M, et al. Among authors: johnston sr. Clin Cancer Res. 1995 Dec;1(12):1511-5. Clin Cancer Res. 1995. PMID: 9815951 Clinical Trial.

6

Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.

Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC. Johnston SR, et al. Clin Cancer Res. 1999 Feb;5(2):251-6. Clin Cancer Res. 1999. PMID: 10037172

7

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE. Dowsett M, et al. Among authors: johnston sr. Clin Cancer Res. 1999 Sep;5(9):2338-43. Clin Cancer Res. 1999. PMID: 10499602 Clinical Trial.

8

Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.

Johnston SR. Johnston SR. Clin Cancer Res. 2001 Dec;7(12 Suppl):4376s-4387s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916228 Review.

9

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M. Johnston SR, et al. Clin Cancer Res. 2003 Jan;9(1 Pt 2):524S-32S. Clin Cancer Res. 2003. PMID: 12538510 Review.

10

Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.

Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR. Leary AF, et al. Among authors: johnston sr. Clin Cancer Res. 2010 Mar 1;16(5):1486-97. doi: 10.1158/1078-0432.CCR-09-1764. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179226

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,405 results

Search Page

Filters